Earnings Feed
Start Free
Home/Filings/4/0001264124-12-000192
4//SEC Filing

KOLTERMAN ORVILLE G 4

Accession 0001264124-12-000192

CIK 0000881464other
View on SEC.govCompany Profile

Filed

Aug 9, 8:00 PM ET

Accepted

Aug 10, 6:37 PM ET

Size

57.0 KB

Accession

0001264124-12-000192

Insider Transaction Report

Form 4
Period: 2012-08-08
AMYLIN PHARMACEUTICALS INCAMLN
KOLTERMAN ORVILLE G
Sr VP Clinical and Regulatory
Transactions
  • Other

    Common Stock

    2012-08-08$31.00/sh+71,349$2,211,819→ 263,909.9 total
  • Disposition from Tender

    Common Stock

    2012-08-08$31.00/sh−192,145.9$5,956,523→ 415 total
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−2,418$74,958→ 0 total
    Exercise: $41.34From: 2007-05-16Exp: 2016-05-16→ Common Stock (2,418 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−19,781$613,211→ 0 total
    Exercise: $15.03Exp: 2018-03-01→ Common Stock (19,781 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−5,219$161,789→ 0 total
    Exercise: $15.03Exp: 2018-03-01→ Common Stock (5,219 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−7,901$244,931→ 0 total
    Exercise: $16.02Exp: 2019-03-06→ Common Stock (7,901 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−6,644$205,964→ 0 total
    Exercise: $18.01Exp: 2017-02-02→ Common Stock (6,644 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−4,020$124,620→ 0 total
    Exercise: $24.87Exp: 2015-03-04→ Common Stock (4,020 underlying)
  • Disposition from Tender

    Common Stock

    2012-08-08$31.00/sh−415$12,865→ 0 total
  • Other

    Common Stock

    2012-08-08$31.00/sh−71,349$2,211,819→ 192,560.9 total
  • Disposition from Tender

    Common Stock

    2012-08-08$31.00/sh−12,767.3$395,786→ 0 total(indirect: By 401(k))
  • Disposition from Tender

    Common Stock

    2012-08-08$31.00/sh−4,984.3$154,513→ 2,990.1 total(indirect: by ESOP)
  • Disposition from Tender

    Common Stock

    2012-08-08$31.00/sh−2,990.1$92,693→ 0 total(indirect: by ESOP)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−6,162$191,022→ 0 total
    Exercise: $16.54From: 2005-05-25Exp: 2015-05-25→ Common Stock (6,162 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−4,424$137,144→ 0 total
    Exercise: $22.60From: 2004-05-04Exp: 2014-05-04→ Common Stock (4,424 underlying)
  • Expiration (Short)

    Incentive Stock Option (right to buy)

    2012-08-08−2,711→ 0 total
    Exercise: $36.90Exp: 2017-03-07→ Common Stock (2,711 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−57,243$1,774,533→ 0 total
    Exercise: $18.85From: 2003-05-12Exp: 2013-05-12→ Common Stock (57,243 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−60,576$1,877,856→ 0 total
    Exercise: $22.60From: 2004-05-04Exp: 2014-05-04→ Common Stock (60,576 underlying)
  • Other

    Incentive Stock Option (right to buy)

    2012-08-08$31.00/sh−7,757$240,467→ 0 total
    Exercise: $18.85From: 2003-05-12Exp: 2013-05-12→ Common Stock (7,757 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−42,099$1,305,069→ 0 total
    Exercise: $16.02Exp: 2019-03-06→ Common Stock (42,099 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−53,356$1,654,036→ 0 total
    Exercise: $18.01Exp: 2017-02-02→ Common Stock (53,356 underlying)
  • Expiration (Short)

    Non-Qualified Stock Option (right to buy)

    2012-08-08−52,582→ 0 total
    Exercise: $41.34From: 2007-05-16Exp: 2016-05-16→ Common Stock (52,582 underlying)
  • Other

    Performance Shares

    2012-08-08$31.00/sh−35,000$1,085,000→ 0 total
    → Common Stock (35,000 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−42,186$1,307,766→ 0 total
    Exercise: $9.02Exp: 2016-03-04→ Common Stock (42,186 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−58,838$1,823,978→ 0 total
    Exercise: $16.54From: 2005-05-25Exp: 2015-05-25→ Common Stock (58,838 underlying)
  • Other

    Non-Qualified Stock Option (right to buy)

    2012-08-08$31.00/sh−60,980$1,890,380→ 0 total
    Exercise: $24.87Exp: 2015-03-04→ Common Stock (60,980 underlying)
  • Expiration (Short)

    Non-Qualified Stock Option (right to buy)

    2012-08-08−67,289→ 0 total
    Exercise: $36.90Exp: 2017-03-07→ Common Stock (67,289 underlying)
Footnotes (6)
  • [F1]These shares were acquired upon the net share settlement of all vested options held by the reporting person and delivered to B&R Acquisition Company upon the consummation of the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
  • [F2]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, through directly tendering such shares pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Also includes unvested restricted stock units that were cancelled at the effective time of the merger in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
  • [F3]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, through directly tendering such shares pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
  • [F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., the reporting person entered into a support agreement pursuant to which all vested options of the reporting person would be exercised using a net share settlement method with the resulting shares delivered to B&R Acquisition Company. All unvested options were cancelled at the effective time of the merger pursuant to the merger agreement in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
  • [F5]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., all options held by the reporting person with an exercise price above $31.00 per share were cancelled upon consummation of the merger.
  • [F6]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these performance-based restricted stock units, whether or not vested, were canceled prior to consummation of the merger in exchange for the right to receive cash payment for each such restricted stock unit at a price of $31.00 per restricted stock unit.

Documents

1 file

Issuer

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

→
Entity typeother

Related Parties

1
  • filerCIK 0001236394

Filing Metadata

Form type
4
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 6:37 PM ET
Size
57.0 KB
View on SEC.gov